The genetic and pharmacological inhibition of ERBB3 results in anti-tumorigenic activity in cancer cells, both in vitro and as xenograft [5, 22-27], and sensitizes lung cancer cells [27] and breast cancer cells [28] to lapatinib, a dual TKI of EGFR and ERBB2. The gene discussed is ERBB2; the disease is cancer.